Recently the landscape of single base mutations in diffuse large B cell lymphoma (DLBCL) was described. Here we report the discovery of a gene fusion between TBL1XR1 and TP63, the only recurrent somatic novel gene fusion identified in our analysis of transcriptome data from 96 DLBCL cases. Based on this cohort and a further 157 DLBCL cases analyzed by FISH, the incidence in de novo germinal centre B celllike (GCB) DLBCL is 5% (6/115). The fusion appears exclusive to GCB, and was not seen in 138 non-GCB cases examined (p=0.008, Fisher exact test) but was present at low incidence in follicular lymphoma (1/81). In all 7 cases identified, the 3' end of the fusion consists of exons 4 and onwards of TP63. The recurrence, subtype enrichment and the remarkably conserved nature of the TP63 portion of the fusion suggest an important functional role in the lymphomas that harbor this event.
Introduction
Chromosomal rearrangements are a hallmark of hematological malignancy. The three most recurrent translocations in DLBCL were discovered by examination of karyotypes, with the partner genes identified in the 1980s and 1990s. 1 Translocations involving BCL6, BCL2 and MYC are reported in 30%, 20-30% and up to 10% of de novo DLBCL, respectively 2 .
Recently we, and others, have described the mutational landscape of DLBCL, focusing on single nucleotide variations and small insertion/deletions. [3] [4] [5] Analysis of transcriptomes also offers the opportunity to identify novel fusion gene transcripts
For personal use only. on July 15, 2017 . by guest www.bloodjournal.org From 3 resulting from cryptic chromosomal rearrangements hitherto unsuspected from karyotype analysis, which is limited by resolution and the complexity of the chromosomal events. 6 TP63 is a paralogue of the tumor suppressive transcription factor TP53. 7 In contrast to TP53, TP63 is rarely mutated in malignancy. [8] [9] [10] However, over-expression of ∆ N-TP63, a set of TP63 isoforms lacking the transactivation (TA) domain has been associated with malignancies of epithelial origin. 11, 12 TBL1XR1 encodes a protein that is part of the NCoR/SMRT transcription repressor complex. 13 Recently, deletion of the TBL1XR1 gene locus has been described in DLBCL 4 and primary CNS lymphoma 14 .
Here, we describe a novel recurrent gene fusion involving TP63 and TBL1XR1 discovered during analysis of DLBCL transcriptomes.
Methods
To identify candidate gene fusion transcripts, Trans-ABySS 15 and deFuse 16 were applied to the previously described 3 transcriptome data generated from 96 DLBCL and 13 FL cases. Validation of candidate fusion transcripts was achieved using Sanger sequencing of amplicons produced by reverse transcription-polymerase chain reaction (RT-PCR) with primers specific for the predicted gene fusion (supplemental Table 1 ).
Cell of origin was assigned using gene expression profiling data when available. The tally algorithm 17 was applied to immunohistochemistry (IHC) data to assign cell of origin for the remaining biopsies. (Supplemental Table 2) FISH was performed on tissue microarrays as previously described 18 . Separate breakapart assays were performed for TBL1XR1 and TP63 (for probe design see supplemental Table 3 ). Images, captured using the Ariol imaging system (Leica Table 4 ). The study was approved by the University of British Columbia-BC Cancer Agency Research Ethics Board.
Results and Discussion
We identified evidence for fusion transcripts from massively parallel RNA sequencing (RNA-seq) of pretreatment de novo DLBCL biopsies. A novel gene fusion involving TBL1XR1 and TP63 was seen in the tumors from 4 patients (Figure 1 ). The existence of the TBL1XR1/TP63 fusion was validated in all 4 cases by Sanger sequencing of amplicons generated using RT-PCR. The breakpoints in the genomic DNA were identified in all cases ( Figure 1B ) and the genetic rearrangement was shown to be somatic by PCR and by whole genome shotgun sequencing of the constitutional DNA of one case.
The TBL1XR1/TP63 fusion was the only recurrent novel somatic gene fusion observed.
TBL1XR1 and TP63 are located 12 Mb apart on the long arm of chromosome 3, flanking the BCL6 locus. To determine the incidence of this genetic rearrangement, FISH was performed on tissue microarrays (TMA) comprising cores of pretreatment de novo DLBCL biopsies of 187 patients. The 30-patient overlap between the RNA-seq cohort and the TMA showed that RNA-seq and FISH had 100% concordance in detecting the TBL1XR1/TP63 fusion in these samples (Figure 2A ). The TMA analysis also revealed two new fusion-containing cases that displayed breakapart of both TBL1XR1 and TP63 loci. Sanger sequencing of amplicons generated using RT-PCR from RNA extracted from the formalin-fixed paraffin-embedded biopsy (Figure 2A ) confirmed the presence of the For personal use only. on July 15, 2017. by guest www.bloodjournal.org From gene fusion in both cases. In aggregate, the incidence of the TBL1XR1/TP63 fusion was 6/115 (5%) cases of GCB DLBCL. The fusion appeared to be exclusive to GCB DLBCL with no TBL1XR1/TP63 fusions seen in 138 cases of non-GCB DLBCL (p=0.008, Fisher exact) ( Figure 2B ).
The shared mutational landscape between GCB DLBCL and FL led us to determine the incidence of the fusion in FL. The TBL1XR1/TP63 fusion was predicted and confirmed using RNA-seq data in one of 13 FLs. FISH was performed on a TMA comprising cores of FL biopsies of 68 patients. The results, with no cases identified where both TBL1XR1 and TP63 loci displayed breakapart, indicate that the fusion is a rare event in FL.
With TBL1XR1 encoded from the negative DNA strand and TP63 from the positive DNA strand, the chromosomal rearrangement event(s) include an inversion that produces gene fusions encoded on the same strand ( Figure 1B) . In all cases, the identified junctions between the TBL1XR1/TP63 exons preserve the distal reading frame.
Suggestive of functional significance, the TP63 portion of the gene fusion is conserved across all seven cases, encoding exons 4 onwards. In five of the DLBCL cases, the 5' junction point is the 3' end of exon 7 of TBL1XR1, with exon 14 in the remaining DLBCL case and exon 4 in the FL case. In contrast, the predicted corollary, TP63/TBL1XR1, is disrupted in three of the four DLBCL cases examined. The mechanisms include a subsequent chromosomal translocation, deletion of the 3' TBL1XR1 portion and skipping of exon 8 of TBL1XR1 producing a frameshift resulting in a truncated protein.
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The observation that the expression of the TBL1XR1/TP63 fusion was 5.2 ± 0.5 fold (mean ± SEM) higher than the wild type TBL1XR1 mRNA, using quantitative RT-PCR on three of the DLBCL cases, suggests that there is a contextual change in the control of the TBL1XR1 promoter, which is driving the expression of this fusion.
The recurrent nature of the TBL1XR1/TP63 gene fusion, the conserved nature of the TP63 portion of the fusion and its exclusive detection in the GCB subtype, suggest a role in the pathogenesis of lymphomas harboring this event. Concomitant alterations of other genes known to be involved in the pathogenesis of DLBCL are given in supplemental Table 5 . TP63 has two major sets of isoforms, distinguished at the Nterminus by the presence (TA-TP63) or lack (∆N-TP63) of the TA domain, encoded by the first three exons. 7 The TA-TP63 isoform has overlapping function with TP53
regarding induction of apoptosis in response to genotoxic stress. Table   6 ). With the observation of deletion of the TBL1XR1 locus in DLBCL 4 and CNS lymphoma 14 , the disruption of TBL1XR1 function represents another possible mechanism of action. On activation, the E3 ligase activity of TBL1XR1 polyubiquinates the NCoR/SMRT complex, thus targeting it for degradation, releasing transcriptional All genomic co-ordinates correspond to the GRCh37 (hg19) human genome assembly. 
